About seqWell
seqWell is a company based in Beverly (United States) founded in 2014 by Jack Leonard. seqWell has raised $24.51 million across 6 funding rounds from investors including Codexis, Broadoak Capital Partners and Research Corporation Technologies. seqWell offers products and services including ExpressPlex™ 2.0, Tagify™, and purePlex™. seqWell operates in a competitive market with competitors including Neogen, LGC, RareCyte, Paragon Genomics and Biotangents, among others.
- Headquarter Beverly, United States
- Founders Jack Leonard
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Seqwell, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.51 M (USD)
in 6 rounds
-
Latest Funding Round
$3.12 M (USD), Series C
Sep 16, 2024
-
Investors
Codexis
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of seqWell
seqWell offers a comprehensive portfolio of products and services, including ExpressPlex™ 2.0, Tagify™, and purePlex™.
Enables quick NGS library preparation with multiplexing for research.
Provides custom-loaded transposase for efficient genomic workflows.
Offers auto-normalization for streamlined sequencing sample processing.
People of seqWell
Unlock access to complete
Unlock access to complete
Funding Insights of seqWell
seqWell has successfully raised a total of $24.51M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $3.12 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in seqWell
seqWell has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Codexis, Broadoak Capital Partners and Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research Corporation Technologies is engaged in licensing biomedical technologies.
|
Locked | Locked | Locked | |
|
High-performance enzymes are developed for drug discovery and biotherapeutics.
|
Locked | Locked | Locked | |
|
Investment banking services are offered in the United States.
|
Locked | Locked | Locked |
Investor details for seqWell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by seqWell
Investment portfolio details for seqWell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - seqWell
Detailed financials for seqWell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Seqwell Comparisons
Peer comparison for seqWell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of seqWell
seqWell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neogen, LGC, RareCyte, Paragon Genomics and Biotangents, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
|
| Locked | Locked | Locked |
Molecular biology reagents and services are supplied to biotech industries.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Provider of technologies and solutions genomic research and precision medicine
|
|
| Locked | Locked | Locked |
Veterinary diagnostics products are developed for bovine viral diarrhea testing.
|
Detailed competitors of seqWell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Seqwell
Complete news archive for seqWell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about seqWell
seqWell was founded in 2014 and raised its 1st funding round 2 years after it was founded.
seqWell is headquartered in Beverly, United States. It is registered at Beverly, Massachusetts, United States.
seqWell is a funded company, having raised a total of $24.51M across 6 funding rounds to date.
SeqWell was founded in 2014 and is headquartered in Beverly, United States. Reagents and kits based on next-generation sequencing (NGS) technology are provided for life sciences research applications. The plexWell platform has been developed to support parallelized library preparation, enabling multiplexing of hundreds to thousands of samples. This Illumina-compatible technology facilitates increased sample throughput on benchtop NGS instruments. Operations focus on simplifying sample preparation processes in the biotechnology sector.
seqWell's top competitors include Neogen, Paragon Genomics and Biotangents.
seqWell offers ExpressPlex™ 2.0, Tagify™, and purePlex™.
seqWell has 4 investors. Key investors include Codexis, Broadoak Capital Partners, Research Corporation Technologies, and Current Investors.